| 1 |
<table width="100%" border="0" cellspacing="2"> |
<p><b>Research & Development at PLIVA</b></p> |
| 2 |
<tr> |
<p><b>Vision</b></p> |
| 3 |
<td> |
<ul> |
| 4 |
<p><img src="p/110.jpg" width="150" height="95" align="left" vspace="5" hspace="3" border="1"><font size="2" face="Arial, Helvetica, sans-serif" color="#000080">This |
<li>To become a leading company in anti-infective research</li> |
| 5 |
year's Organic Chemistry Award Vladimir |
<li>To become an internationally recognized center for inflammation research</li> |
| 6 |
Prelog was presented to Valerije Vrcek, |
<li>To generate NMEs with the objective of producing commercial returns in line |
| 7 |
Ph.D., a young scientist from the Faculty |
with the PLIVA's growth targets</li> |
| 8 |
of Pharmacy and Biochemistry in Zagreb for |
<li>To develop novel drugs which will serve as yet unmet medical needs at launch</li> |
| 9 |
his exceptional contribution to synthesis |
</ul> |
| 10 |
of nucleosides, understanding of carbocationic |
<p align="center"><img src="p/Superrnd_ljudi_4.jpg" width="300" height="198"></p> |
| 11 |
rearrangements and NMR spectroscopy of organic |
<p><b>Strategy</b></p> |
| 12 |
molecules. The Vladimir Prelog Organic Chemistry |
<p>Within the last five years, PLIVA has been undergoing a vigorous process of |
| 13 |
Award was established in 1996 as a means |
change to reshape its R&D operations in order to meet international standards |
| 14 |
of encouragement for young Croatian scientists |
and future global challenges. PLIVA sees its continued R&D success as being |
| 15 |
in the field of organic chemistry. It was |
based on the combination of its international research team in Zagreb, a network |
| 16 |
founded by PLIVA and the Croatian Chemical |
of strategic partnerships with multinational and biotech companies, and broad |
| 17 |
Society to mark 90 years of the birth of |
co-operation with various international universities and institutes. In addition, |
| 18 |
Vladimir Prelog, the renowned Croatian scientist |
PLIVA's R&D locations at PLIVA Lachema (Brno, the Czech Republic) and PLIVA |
| 19 |
and Nobel Prize Winner.This year's Organic |
Krakow (Krakow, Poland) give it unique access to experience and skills, particularly |
| 20 |
Chemistry Award Vladimir</font></p> |
in the development of NCEs and generics. Furthermore, local presence on the |
| 21 |
<p><font size="2" face="Arial, Helvetica, sans-serif" color="#000080"> |
developing markets of Central and Eastern Europe will give PLIVA a competitive |
| 22 |
Prelog was presented to Valerije Vrcek, |
advantage in the development and registration of its products.</p> |
| 23 |
Ph.D., a young scientist from the Faculty |
<p>At its main research location in Zagreb, PLIVA maintains all the necessary |
| 24 |
of Pharmacy and Biochemistry in Zagreb for |
technology for synthetic chemistry, structure based drug design, molecular biology, |
| 25 |
his exceptional contribution to synthesis |
pharmacology, toxicology, process development and pharmaceutical technology. |
| 26 |
of nucleosides, understanding of carbocationic |
This enables accurate evaluation of compounds and research proposals at early |
| 27 |
rearrangements and NMR spectroscopy of organic |
stages and allows more rapid movement toward clinical development. In general, |
| 28 |
molecules. The Vladimir Prelog Organic Chemistry |
PLIVA is looking to bring projects from the Discovery stage to Phase II clinical |
| 29 |
Award was established in 1996</font><font size="2" face="Verdana, Arial, Helvetica, sans-serif" color="#000080"> |
trials, thereafter seeking a partner for global development and marketing.</p> |
|
</font></p> |
|
|
</td> |
|
|
</tr> |
|
|
<tr> |
|
|
<td height="2"> |
|
|
<hr size="1" width="100%"> |
|
|
</td> |
|
|
</tr> |
|
|
<tr valign="top"> |
|
|
<td> |
|
|
<p align=justify><img height=100 hspace=3 |
|
|
src="p/str1.gif" width=150 align=left border=1 vspace="5"><font face="Arial, Helvetica, sans-serif" color="#000080" size="2">Research |
|
|
and Development is central to both PLIVA's |
|
|
past and future success. For that reason, |
|
|
PLIVA pays careful attention to the organization |
|
|
of R&D activities, ensuring that research |
|
|
and development activities are closely aligned |
|
|
to the company's core business.<br> |
|
|
<br> |
|
|
The prime goal of research at PLIVA is the |
|
|
development of new chemical entities which |
|
|
can be developed into innovative medicines |
|
|
to combat illness and improve the quality |
|
|
of life for people around the world. Our |
|
|
researchers, assistants and lab technicians |
|
|
as well as all employees at PLIVA understand |
|
|
that our primary task is helping people.</font> |
|
|
<p align=justify><font face="Arial, Helvetica, sans-serif" color="#000080" size="2">PLIVA's |
|
|
blockbuster antibiotic <b>azithromycin</b> |
|
|
is a good example of how the dedication |
|
|
of the PLIVA's R&D staff brought about |
|
|
the discovery and development of a medicine |
|
|
which is now fighting disease worldwide, |
|
|
sold as <b>Sumamed</b> by PLIVA and licensed |
|
|
to Pfizer which markets it as <b>Zithromax</b>. |
|
|
At this very moment, the staff of PLIVA's |
|
|
research institute are working on new, innovative |
|
|
and original medicines which will carry |
|
|
on PLIVA's battle against disease.</font> |
|
|
</td> |
|
|
</tr> |
|
|
<tr> |
|
|
<td height="2"> |
|
|
<hr size="1" width="100%"> |
|
|
</td> |
|
|
</tr> |
|
|
<tr valign="top"> |
|
|
<td> |
|
|
<table cellspacing=0 cellpadding=0 width=360 border=0> |
|
|
<tbody> |
|
|
<tr> |
|
|
<td width=70 height="66"><img height=90 |
|
|
src="p/portret_spaventi.gif" width=70 border=0></td> |
|
|
<td width=15 height="66"></td> |
|
|
<td valign=top align=left width=275 height="66"><br> |
|
|
<font face=Arial color=#000080 size=1>RADAN |
|
|
SPAVENTI, M.D., Ph.D.<br> |
|
|
Research & Development, Direcor<br> |
|
|
Management Board, Vice President for |
|
|
R&D<br> |
|
|
Phone: 3851/3781 078<br> |
|
|
Fax: 3851/370 3175<br> |
|
|
E-mail: <a |
|
|
href="mailto:radan.spaventi@pliva.hr">radan.spaventi@pliva.hr</a><br> |
|
|
</font> </td> |
|
|
</tr> |
|
|
</tbody> |
|
|
</table> |
|
|
</td> |
|
|
</tr> |
|
|
<tr> |
|
|
<td height="2"> |
|
|
<hr size="1" width="100%"> |
|
|
</td> |
|
|
</tr> |
|
|
<tr> |
|
|
<td> |
|
|
<table cellspacing=0 cellpadding=0 width=360 border=0> |
|
|
<tbody> |
|
|
<tr> |
|
|
<td width=70 height="86"><img height=81 |
|
|
src="p/portret_kovacevic.gif" width=70 |
|
|
border=0></td> |
|
|
<td width=15 height="86"></td> |
|
|
<td valign=top align=left width=275 height="86"><br> |
|
|
<font face=Arial color=#000080 size=1>KRUNOSLAV |
|
|
KOVACEVIC, Ph. D. Chem.<br> |
|
|
Research & Development, Deputy to |
|
|
Director<br> |
|
|
Phone: 3851/3781 105, 3781 027<br> |
|
|
Fax: 3851/3703 175<br> |
|
|
E-mail: <a |
|
|
href="mailto:kruno.kovacevic@pliva.hr">kruno.kovacevic@pliva.hr</a><br> |
|
|
</font> </td> |
|
|
</tr> |
|
|
</tbody> |
|
|
</table> |
|
|
</td> |
|
|
</tr> |
|
|
<tr> |
|
|
<td height="2"> |
|
|
<hr size="1" width="100%"> |
|
|
</td> |
|
|
</tr> |
|
|
<tr> |
|
|
<td> |
|
|
<table cellspacing=0 cellpadding=0 width=360 border=0> |
|
|
<tbody> |
|
|
<tr> |
|
|
<td width=70><img height=81 src="p/portret_kolega.gif" width=70 border=0></td> |
|
|
<td width=15></td> |
|
|
<td valign=top align=left width=275><br> |
|
|
<font face=Arial color=#000080 size=1>MARKO |
|
|
KOLEGA, M.D., Ph.M.<br> |
|
|
Research & Development, Deputy to |
|
|
Director (+ New Res. Institute Building)<br> |
|
|
Phone: 3851/3781 163, 3781 098<br> |
|
|
Fax: 3851/3703 175<br> |
|
|
GSM/Cell: 38598/289 283<br> |
|
|
E-mail: <a href="mailto:marko.kolega@pliva.hr">marko.kolega@pliva.hr</a><br> |
|
|
</font> </td> |
|
|
</tr> |
|
|
</tbody> |
|
|
</table> |
|
|
</td> |
|
|
</tr> |
|
|
</table> |
|
Parent Directory
| 
Revision Log
| 
Patch